相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- The National Institute for Health and Care Excellence (NICE) has approved Talquetamab for NHS use, making this breakthrough blood cancer treatment available to up to 800 multiple myeloma patients annually. - Sue Harley, a Birmingham grandmother diagnosed with myeloma in 2017, achieved remission after receiving Talquetamab through a compassionate use program following failure of five previous treatment lines. - Multiple myeloma is the third most common blood cancer but remains difficult to detect as symptoms often mimic general aging or minor conditions. - The approval represents a significant advance in blood cancer treatment, providing patients with additional therapeutic options and renewed hope for long-term disease control.
- The ImmunoTACE phase II trial demonstrated that patients with intermediate-stage hepatocellular carcinoma who received dendritic cell vaccination alongside standard treatment experienced significantly longer progression-free survival at 18.6 months versus 10.4 months with standard care alone. - This represents the first controlled clinical trial to show that a cell-based vaccine using lab-grown dendritic cells can improve patient outcomes in liver cancer, offering a potential new treatment approach for one of the world's leading causes of cancer-related death. - The vaccine is created from patients' own white blood cells, expanded in laboratory conditions with cancer proteins to stimulate immune responses, and represents a potentially affordable and effective therapy that could complement existing checkpoint inhibitor treatments.
- A Feinstein Institutes study demonstrates that culturally tailored telemonitoring interventions significantly improve participation among Hispanic and Latinx communities with type 2 diabetes, reducing HbA1c levels from 8.32% to 7.55%. - Language barriers and inflexible trial designs emerge as major obstacles for including underrepresented communities, with Hispanic adults showing nearly twice the diabetes prevalence (11.7%) compared to non-Hispanic whites (6.9%). - Experts emphasize the need for adaptable scheduling, culturally relevant educational materials, and revised inclusion criteria to better accommodate minority populations in diabetes clinical trials.
